<a href="https://laohu8.com/S/SION">Sionna Therapeutics</a> reports third quarter 2025 results
Sionna Therapeutics Inc. reported a net loss of $20.3 million for the third quarter of 2025, compared to a net loss of $25.4 million in the third quarter of 2024. Research and development expenses were $16.0 million, down from $24.6 million in the prior year period, mainly due to one-time charges recognized in the previous year. General and administrative expenses rose to $7.8 million from $3.4 million, primarily due to increased personnel-related costs, professional fees, and stock-based compensation. The company held $325.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects this to fund operations into 2028. During the period, Sionna initiated a Phase 2a trial of SION-719 in cystic fibrosis, completed a drug-drug interaction study, and began a Phase 1 trial evaluating SION-451 in combination regimens. Topline data from both trials are anticipated in mid-2026. In September 2025, Caroline Stark Beer was appointed Chief Business Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568658-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.